It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Moshfeghi reports the following financial relationships:
Advisory Roles / Data Safety Monitoring Board (DSMB):
Clinical Trials Resource Group (DSMB); Icon Clinical Research LLC (DSMB); InGel Therapeutics (DSMB); Insite DME (DSMB); and Vanotech Chengdu (DSMB)
Consultant: Ocular Therapeutix, Inc.
Grants/Research Support (paid to institution): Genentech, Inc. Research to Prevent Blindness, Inc. NEI P30-EY026877
Equity / Ownership Interests: Ainsly Limited (direct equity shares; holding company); DSENTZ, Inc. (direct equity shares; currently non-operational); Osanni Bio (stock options; retinal therapeutic development); Plenoptika, Inc. (stock options; ophthalmic medical device company); PR3VENT (direct equity shares; screening technology company); Pykus Therapeutics Inc. (stock options; vitreous substitute development); RetinaBio, Inc. (stock options; retinal nutraceutical development); and Vision Labs Inc. (direct equity shares; anterior segment diagnostic device company); Grand Legend Technology, LTD and Visunex are defunct entities.
Other Financial Relationships: Board of Directors – GIGGU
Dr. Coney reports the following financial relationships:
Advisory Board: Abbvie Inc./Allergan, Inc.; Alimera Sciences, Inc. (ended 2/2025); ANI Pharmaceuticals, Inc.; Apellis Pharmaceuticals, Inc.; Astellas Pharma Inc./Iveric Bio Inc.; Genentech, Inc./Roche; Ocular Therapeutix, Inc.; and
Regeneron Pharmaceuticals Inc.
Consultant: AbbVie Inc./Allergan, Inc.; Alimera Sciences, Inc. (ended 2/2025); Apellis Pharmaceuticals, Inc.; Bausch & Lomb Americas, Inc.; Coherus Biosciences, Inc.; Genentech, Inc./Roche; and Regeneron Pharmaceuticals Inc.
Research Support: 4DMT; AbbVie Inc./Allergan, Inc.; Alimera Sciences, Inc. (ended 2/2025); Apellis Pharmaceuticals, Inc.; Aviceda Therapeutics; Eyebiotech Limited; Genentech, Inc./Roche; Hoffman LaRoche, Ltd.; MacTel; National Eye Institute; Regeneron Pharmaceuticals Inc.; and Regenxbio Inc.
Speakers Bureau: 4DMT; AbbVie Inc./Allergan, Inc.; Alimera Sciences, Inc. (ended 2/2025); ANI Pharmaceuticals, Inc.; Apellis Pharmaceuticals, Inc.; Astellas Pharma Inc./Iveric Bio, Inc.; Bausch & Lomb Americas, Inc.; Genentech, Inc./Roche; Ocular Therapeutix, Inc.; and Regeneron Pharmaceuticals Inc.
The following individuals have no financial relationships to disclose:
Jeffrey Helfand, DO (Peer Reviewer)
Natasha Caudill (Patient Planner)
Susan Perry (Planning Committee)
Warren Beckman (Planning Committee)
Siddharth Mohan, MPH (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
